scholarly journals Effect of Two Novel Sustained-Release Drug Delivery Systems on Bleb Fibrosis: An In Vivo Glaucoma Drainage Device Study in a Rabbit Model

2015 ◽  
Vol 4 (3) ◽  
pp. 4 ◽  
Author(s):  
Evan D. Schoenberg ◽  
Diane A. Blake ◽  
F. Beau Swann ◽  
Andrew W. Parlin ◽  
David Zurakowski ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Sustained Release ◽  
Drug Delivery Systems ◽  
Rabbit Model ◽  
Delivery Systems ◽  
Glaucoma Drainage Device ◽  
Drainage Device ◽  
Release Drug

scholarly journals Bimatoprost-Loaded Ocular Inserts as Sustained Release Drug Delivery Systems for Glaucoma Treatment: In Vitro and In Vivo Evaluation

PLoS ONE ◽  
2014 ◽  
Vol 9 (4) ◽  
pp. e95461 ◽  
Author(s):  
Juçara Ribeiro Franca ◽  
Giselle Foureaux ◽  
Leonardo Lima Fuscaldi ◽  
Tatiana Gomes Ribeiro ◽  
Lívia Bomfim Rodrigues ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Sustained Release ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
In Vivo Evaluation ◽  
Release Drug ◽  
Glaucoma Treatment

scholarly journals Sustained-release drug delivery systems for the treatment of glaucoma

2021 ◽  
Vol 14 (1) ◽  
pp. 148-159
Author(s):  
Natasha P. Kesav ◽  
◽  
Monica K. Ertel ◽  
Leonard K. Seibold ◽  
Malik Y. Kahook ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Sustained Release ◽  
Targeted Delivery ◽  
Drug Delivery Systems ◽  
Patient Adherence ◽  
The United States ◽  
Delivery Systems ◽  
Release Drug ◽  
Systemic Side Effects

Glaucoma, a leading cause of irreversible blindness, affects more than 64 million people worldwide and is expected to grow in number due to the aging global population and enhanced methods of detection. Although topical therapies are often effective when used as prescribed, the drawbacks of current medical management methods include poor patient adherence, local and systemic side effects, and in some cases, limited therapeutic efficacy. Novel ocular drug delivery platforms promise to deliver differentiated drug formulations with targeted delivery leveraging patient-independent administration. Several platforms are in various stages of development with promising pre-clinical and clinical data. The Bimatoprost Sustained Release (SR) intracameral implant was approved in the United States in March of 2020, making it the first long-term injectable therapy available for the treatment of glaucoma. This review aims to provide an update on novel sustained release drug delivery systems that are available today as well as those that might be commercialized in coming years.

scholarly journals Development andin vitrocharacterization of floating sustained-release drug delivery systems of polyphenols

Drug Delivery ◽  
2013 ◽  
Vol 20 (3-4) ◽  
pp. 180-189 ◽  
Author(s):  
Ohad Rosenzweig ◽  
Eran Lavy ◽  
Irith Gati ◽  
Ron Kohen ◽  
Michael Friedman
Keyword(s):  
Drug Delivery ◽  
Sustained Release ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Release Drug

Sustained-Release Drug Delivery Systems of Chinese Medicines

2021 ◽  
pp. 49-76
Author(s):  
Xiao Zheng ◽  
Teng Guo ◽  
Fei Wu ◽  
Lan Shen ◽  
Xiao Lin
Keyword(s):  
Drug Delivery ◽  
Sustained Release ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Chinese Medicines ◽  
Release Drug

scholarly journals Electrospun organic–inorganic nanohybrids as sustained release drug delivery systems

2017 ◽  
Vol 5 (46) ◽  
pp. 9165-9174 ◽  
Author(s):  
Yanshan Gao ◽  
Tian Wei Teoh ◽  
Qiang Wang ◽  
Gareth R. Williams
Keyword(s):  
Drug Delivery ◽  
Drug Release ◽  
Sustained Release ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Release Drug

Novel organic–inorganic nanohybrids have been prepared, and are found to provide long-term extended drug release.

Sign in / Sign up

Export Citation Format

Share Document